Article Text

Download PDFPDF
The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study
  1. A Finckh1,
  2. S Dehler2,
  3. C Gabay1
  1. 1
    Department of Medicine, Division of Rheumatology, Geneva University Hospital, Geneva, Switzerland
  2. 2
    SCQM Foundation, Department of Social and Preventive Medicine, University of Zurich, Switzerland
  1. Dr A Finckh/Dr C Gabay, Division of Rheumatology, Department of Internal Medicine, University Hospital of Geneva, 26 Av. Beau-Sejour, 1211 Geneva 14. Switzerland; axel.finckh{at}hcuge.ch or cem.gabay{at}hcuge.ch

Footnotes

  • Competing interests: None declared.

  • Funding: AF was funded by a research grant from the Geneva University. SD was funded by the SCQM Foundation. CG by the Swiss National Science Foundation (Grant no. 320000-107592). This study was further partially supported by an unrestricted research grant from Sanofi-Aventis. The SCQM Foundation has received grants from the Swiss Health authorities (BAG), the Swiss Academy for Medical Sciences (SAMW), the JL Warnery Foundation, the Swiss Society of polyarthritic patients (SPV) and pharmaceutical companies (Abbott, Essex, Wyeth, Roche, Bristol-Myers Squibb, Mepha, Novartis, Sanofi-Aventis).

View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests: None declared.

  • Funding: AF was funded by a research grant from the Geneva University. SD was funded by the SCQM Foundation. CG by the Swiss National Science Foundation (Grant no. 320000-107592). This study was further partially supported by an unrestricted research grant from Sanofi-Aventis. The SCQM Foundation has received grants from the Swiss Health authorities (BAG), the Swiss Academy for Medical Sciences (SAMW), the JL Warnery Foundation, the Swiss Society of polyarthritic patients (SPV) and pharmaceutical companies (Abbott, Essex, Wyeth, Roche, Bristol-Myers Squibb, Mepha, Novartis, Sanofi-Aventis).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.